Huang Chen, Li Yongsheng, Zhang Baozhong, Tang Yukuan, Huang Yuyang, Wei Wei
Minimally Invasive Intervention Department, The Affiliated Panyu Central Hospital of Guangzhou Medical University, Guangzhou, China.
Scientific Research Center, Guangdong Cord Blood Bank, Guangzhou, China.
Clin Med Insights Oncol. 2025 Aug 10;19:11795549251365360. doi: 10.1177/11795549251365360. eCollection 2025.
The eradication of tumors remains a critical and challenging issue in medical research. Exosomes (EXOs) derived from various sources have garnered increasing attention in the field of tumor therapy. Among these, cord blood (CB)-derived EXOs may offer unique advantages in combating tumors due to the distinctive properties of CB. This narrative review examines the current application status of CB-derived EXOs in tumor prevention and treatment: in the context of tumor treatment, it focuses on their direct therapeutic application and their use as drug carriers; regarding tumor prevention, it explores their application in cancer vaccines. In addition, it also reviews the specific components of CB from which these EXOs are derived, their particle sizes, characteristic proteins, and the types of tumors to which they have been primarily applied for prevention and treatment. In conclusion, we believe that CB-derived EXOs hold substantial potential for effective tumor prevention and treatment and are likely to emerge as a prominent area of research in the future.
肿瘤的根除仍然是医学研究中的一个关键且具有挑战性的问题。源自各种来源的外泌体（EXOs）在肿瘤治疗领域受到越来越多的关注。其中，由于脐带血（CB）具有独特的特性，源自脐带血的外泌体在对抗肿瘤方面可能具有独特优势。这篇叙述性综述探讨了源自脐带血的外泌体在肿瘤预防和治疗中的当前应用状况：在肿瘤治疗方面，重点关注其直接治疗应用以及作为药物载体的用途；关于肿瘤预防，探讨了它们在癌症疫苗中的应用。此外，还综述了这些外泌体所源自的脐带血的具体成分、粒径、特征性蛋白质以及它们主要应用于预防和治疗的肿瘤类型。总之，我们认为源自脐带血的外泌体在有效的肿瘤预防和治疗方面具有巨大潜力，并且很可能在未来成为一个突出的研究领域。
